This document discusses tools for calculating sample size, including the free PS2 program and StatCalc program. It explains that sample size calculation depends on study design, and directs the reader to other sections that describe how to calculate sample size for different study designs like cross-sectional, case-control, cohort, and clinical trials. References are provided for further information.
Introduction to meta-analysis (1612_MA_workshop)Ahmed Negida
Chapter 1: Introduction to Meta-analysis
- From the 1612 MA Workshop that will be held on 11th, December, 2016 at Dokki, Giza, Egypt
- Workshop instructor: Mr. Ahmed Negida, MBBCh candidate
Meta-analysis in Epidemiology is:
Useful tool for epidemiological studies which investigates the relationships between certain risk factors and disease.
Useful tool to improve animal well-being and productivity
Despite of a wealth of suitable studies it is relatively underutilized in animal and veterinary science.
Meta-analysis can provide reliable results about diseases occurrence, pattern and impact in livestock.
It is utmost essential to take benefit of this statistical tool for produce. more reliable estimates of concern effects in animal and veterinary science data.
Introduction to meta-analysis (1612_MA_workshop)Ahmed Negida
Chapter 1: Introduction to Meta-analysis
- From the 1612 MA Workshop that will be held on 11th, December, 2016 at Dokki, Giza, Egypt
- Workshop instructor: Mr. Ahmed Negida, MBBCh candidate
Meta-analysis in Epidemiology is:
Useful tool for epidemiological studies which investigates the relationships between certain risk factors and disease.
Useful tool to improve animal well-being and productivity
Despite of a wealth of suitable studies it is relatively underutilized in animal and veterinary science.
Meta-analysis can provide reliable results about diseases occurrence, pattern and impact in livestock.
It is utmost essential to take benefit of this statistical tool for produce. more reliable estimates of concern effects in animal and veterinary science data.
Extending A Trial’s Design Case Studies Of Dealing With Study Design IssuesnQuery
About the webinar
As trials increase in complexity and scope, there is a requirement for trial designs to reflect this.
From dealing with non-proportional hazards in survival analysis to dealing with cluster randomization, we examine how to deal with study design issues of complex trials.
In this free webinar, you will learn about:
Dealing with study design issues
Practical worked examples of
Non-proportional Hazards
Cluster Randomization
Three Armed Trials
Non-proportional Hazards
Non-proportional hazards and complex survival curves have become of increasing interest, due to being commonly seen in immunotherapy development. This has led to interest in assessing the robustness of standard methods and alternative methods that better adapt to deviations.
In this webinar, we look at methods proposed for complex survival curves and the weighted log-rank test as a candidate model to deal with a delayed survival effect.
Cluster Randomization
Cluster-randomized designs are often adopted when there is a high risk of contamination if cluster members were randomized individually. Stepped-wedge designs are useful in cases where it is difficult to apply a particular treatment to half of the clusters at the same time.
In this webinar, we introduce cluster randomization and stepped-wedge designs to provide an insight into the requirements of more complex randomization schedules.
Three Armed Trials
Non-inferiority testing is a common hypothesis test in the development of generic medicine and medical devices. The most common design compares the proposed non-inferior treatment to the standard treatment alone but this leaves uncertain if the treatment effect is the same as from previous studies. This “assay sensitivity” problem can be resolved by using a three arm trial which includes placebo alongside the new and reference treatments for direct comparison.
In this webinar we show a complete testing approach to this gold standard design and how to find the appropriate allocation and sample size for this study.
Duration - 60 minutes
Speaker: Ronan Fitzpatrick, Head of Statistics, Statsols
Adaptive Clinical Trials: Role of Modelling and Simulation SGS
To increase the efficiency of trials in drug development, optimal experimental design has been used to successfully optimize dose allocation and sampling schedules. Better incremental decisions in Phase I and II result in greater likelihood that the safety and efficacy of the right dose is being studied, for the right indication and in the right patient population. This approach involves a pre-planned adaptation of aspects of study design based on statistical and/or pharmacokinetic/pharmacodynamic (PK/PD) analysis. From a modelling and simulation (M&S) perspective, a prior understanding of concentration (dose)-efficacy and of concentration (dose)-toxicity relationship is needed.
Nowadays Scientists using laboratory animals are under increasing pressure to justify their sample sizes using a ‘‘power analysis’’ to improve study reproducibility and from ethical point of view too.
In this presentation, I review the three methods currently used to determine sample size: ‘‘tradition’’ or ‘‘common sense’’, the ‘‘resource equation’’ and the ‘‘power analysis’’.
2020 trends in biostatistics what you should know about study design - slid...nQuery
2020 Trends In Biostatistics - What you should know about study design.
In this free webinar you will learn about:
-Adaptive designs in confirmatory trials
-Using external data in study planning
-Innovative designs in early-stage trials
To watch the full webinar:
https://www.statsols.com/webinar/2020-trends-in-biostatistics-what-you-should-know-about-study-design
5 essential steps for sample size determination in clinical trials slidesharenQuery
In this free webinar hosted by nQuery Researcher & Statistician Eimear Keyes, we map out the 5 essential steps for sample size determination in clinical trials. At each step, Eimear will highlight the important function it plays and how to avoid the errors that will negatively impact your sample size determination and therefore your study.
Watch the Video: https://www.statsols.com/webinar/the-5-essential-steps-for-sample-size-determination
Optimizing Oncology Trial Design FAQs & Common IssuesnQuery
Optimizing Oncology Trial Design - FAQs & Common Issues
In this free webinar you will learn about
Endpoints
Models
Covariates, stratification and censoring issues
Adaptive design - complications and opportunities
Sample size determination
& more
In this free webinar we will offer guidance on how to optimize your oncology trial design. Specifically, we will examine the frequently asked questions and common issues that arise.
https://www.statsols.com/webinar/optimizing-oncology-trial-design
Practical Methods To Overcome Sample Size ChallengesnQuery
Watch the video at: https://www.statsols.com/webinars/practical-methods-to-overcome-sample-size-challenges
In this webinar hosted by Ronan Fitzpatrick - Head of Statistics and nQuery Lead Researcher at Statsols - we will examine some of the most common practical challenges you will experience while calculating sample size for your study. These challenges will be split into two categories:
1. Overcoming Sample Size Calculation Challenges
(Survival Analysis Example)
We will examine practical methods to overcome common sample size calculation issues by focusing in on one of the more complex areas for sample size determination; Survival analysis. We will cover difficulties and potential issues surrounding challenges such as:
Drop Out: How to deal with expected dropouts or censoring. We compare the simple loss-to-follow-up method and integrating a dropout process into the sample size model?
Planning Uncertainty: How best to deal with the inevitable uncertainty at the planning stage? We examine how best to apply a sensitivity analysis and Bayesian approaches to explore the uncertainty in your sample size calculations.
Choosing the Effect Size: Various approaches and interpretations exist for how to find the effect size value. We examine those contrasting interpretations and determine the best method and also how to deal with parameterization options.
2. Overcoming Study Design Challenges
(Vaccine Efficacy Example)
The Randomised Controlled Trial (RCT) is considered the gold standard in trial design in drug development. However, there are often practical impediments which mean that adjustments or pragmatic approaches are needed for some trials and studies.
We will examine practical methods how to overcome common study design challenges and how these affect your sample size calculations. In this webinar, we will use common issues in vaccine study design to examine difficulties surrounding issues such as:
Case-Control Analysis: We will examine how to deal with study constraints and how to deal with analyses done during an observational study.
Alternative Randomization Methods: How best to address randomization in your vaccine trial design when full randomization is difficult, expensive or impractical. We examine how sample size calculations are affected with cluster or Mendelian randomization.
Rare Events: How does an outcome being rare affect the types of study design and statistical methods chosen in your study.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Acute scrotum is a general term referring to an emergency condition affecting the contents or the wall of the scrotum.
There are a number of conditions that present acutely, predominantly with pain and/or swelling
A careful and detailed history and examination, and in some cases, investigations allow differentiation between these diagnoses. A prompt diagnosis is essential as the patient may require urgent surgical intervention
Testicular torsion refers to twisting of the spermatic cord, causing ischaemia of the testicle.
Testicular torsion results from inadequate fixation of the testis to the tunica vaginalis producing ischemia from reduced arterial inflow and venous outflow obstruction.
The prevalence of testicular torsion in adult patients hospitalized with acute scrotal pain is approximately 25 to 50 percent
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/